Canopy Growth (CGC) Stock
Canadian cannabis producer for medical and adult markets. Here's the price, business snapshot, and what's worth knowing about Canopy Growth in June 2026.
Canopy Growth Corporation (CGC) is a Canadian cannabis producer active in adult‑use and medical markets, with branded products that include flower, oils, edibles and beverages. With a market capitalisation of US$645.37M, the company has shifted focus towards operational efficiency and portfolio rationalisation after several years of heavy investment and restructuring. Key considerations for investors are its exposure to regulatory change (particularly any US federal legalisation), competitive pressure from other licensed producers and consumer packaged goods companies, and ongoing challenges returning to sustained profitability. Liquidity, balance‑sheet strength and execution on cost savings are material variables to monitor. This summary is general educational information and not personal advice; cannabis stocks can be volatile and values may rise or fall. Investors should assess suitability relative to their objectives, risk tolerance and time horizon, and consider seeking regulated financial advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Canopy Growth's stock with a target price of $4.8, indicating potential for growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring CGC
Cannabis Reclassification | Schedule III Tax Relief
The DOJ's historic move to reclassify marijuana as a Schedule III drug is removing massive tax burdens and sparking immediate optimism across the cannabis sector. This policy shift unlocks new profitability and operational pathways for medical producers, dispensaries, and pharmaceutical researchers navigating the newly regulated landscape.
Published: April 24, 2026
Explore BasketCanada Domestic Champions Explained | Trade War Shield
Recent U.S. tariffs have caused a contraction in Canada's export-driven economy, creating a unique investment opportunity. This theme focuses on Canadian companies that serve the domestic market and are insulated from international trade disputes.
Published: August 30, 2025
Explore BasketVice Arbitrage
Get exposure to companies leading the transformation of once-prohibited activities into booming legal industries. These carefully selected stocks represent market leaders capitalizing on shifting regulations in sports betting, cannabis, and more, unlocking tremendous growth potential.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Market recovery watch
Watch for signs of revenue stabilisation and margin improvement as indicators of recovery, though performance can vary and is not guaranteed.
Product innovation
New formats and branded products can drive consumer demand, but success depends on execution, distribution and changing consumer tastes.
Regulatory drivers
Shifts in regulation, especially in the US, could materially change the opportunity set, but regulatory outcomes are uncertain and carry risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
